Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis

Abstract Background We aimed to clarify the benefits of the addition of rh‐endostatin into concurrent chemoradiotherapy (CCRT) versus CCRT alone for locally advanced non‐small cell lung cancer (NSCLC) by a meta‐analysis. Methods PubMed, Embase, Cochrane Central Register of Controlled Trials, Wanfang...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Meng Yuan, Yirui Zhai, Yu Men, Jianyang Wang, Lei Deng, Wenqing Wang, Yongxing Bao, Xu Yang, Shuang Sun, Zeliang Ma, Yunsong Liu, Jun Wang, Hui Zhu, Zhouguang Hui
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	chemoradiotherapy endostar meta‐analysis NSCLC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a597e61c70d744ec9bc1c2305f16b691
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a597e61c70d744ec9bc1c2305f16b691
record_format	dspace
spelling	oai:doaj.org-article:a597e61c70d744ec9bc1c2305f16b6912021-12-02T02:34:55ZEndostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis1759-77141759-770610.1111/1759-7714.14188https://doaj.org/article/a597e61c70d744ec9bc1c2305f16b6912021-12-01T00:00:00Zhttps://doi.org/10.1111/1759-7714.14188https://doaj.org/toc/1759-7706https://doaj.org/toc/1759-7714Abstract Background We aimed to clarify the benefits of the addition of rh‐endostatin into concurrent chemoradiotherapy (CCRT) versus CCRT alone for locally advanced non‐small cell lung cancer (NSCLC) by a meta‐analysis. Methods PubMed, Embase, Cochrane Central Register of Controlled Trials, Wanfang and Chinese National Knowledge Infrastructure (CNKI) were systematically screened from inception to November 2020 using the prespecified terms. Prospective trials (evaluating or) comparing the efficacy of endostar combined with CCRT and CCRT for locally advanced NSCLC were included. The primary endpoints were risk ratios (RRs) for objective response rate (ORR) and disease control rate (DCR). The secondary endpoints were RRs for overall survival (OS) and adverse events (AEs). Results Ten studies with 716 patients were included in this meta‐analysis. Endostar combined with CCRT significantly improved ORR and DCR compared with CCRT. The RRs of ORR and DCR for endostar combined with CCRT versus CCRT were 1.263 (95% CI: 1.137–1.403, p < 0.001) and 1.274 (95% CI: 1.124–1.444, p < 0.001), respectively. Endostar combined with CCRT significantly improved one‐year survival rate compared with CCRT with pooled RR = 1.113 (95% CI: 1.006–1.231, p = 0.038). Endostar combination treatments had similar incidences of main adverse events compared with CCRT (p > 0.05). Conclusion Endostar combined with CCRT is associated with significantly higher ORR, DCR and survival rate than CCRT with similar incidences of main adverse events in NSCLC.Meng YuanYirui ZhaiYu MenJianyang WangLei DengWenqing WangYongxing BaoXu YangShuang SunZeliang MaYunsong LiuJun WangHui ZhuZhouguang HuiWileyarticlechemoradiotherapyendostarmeta‐analysisNSCLCNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENThoracic Cancer, Vol 12, Iss 23, Pp 3208-3215 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chemoradiotherapy endostar meta‐analysis NSCLC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	chemoradiotherapy endostar meta‐analysis NSCLC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Meng Yuan Yirui Zhai Yu Men Jianyang Wang Lei Deng Wenqing Wang Yongxing Bao Xu Yang Shuang Sun Zeliang Ma Yunsong Liu Jun Wang Hui Zhu Zhouguang Hui Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
description	Abstract Background We aimed to clarify the benefits of the addition of rh‐endostatin into concurrent chemoradiotherapy (CCRT) versus CCRT alone for locally advanced non‐small cell lung cancer (NSCLC) by a meta‐analysis. Methods PubMed, Embase, Cochrane Central Register of Controlled Trials, Wanfang and Chinese National Knowledge Infrastructure (CNKI) were systematically screened from inception to November 2020 using the prespecified terms. Prospective trials (evaluating or) comparing the efficacy of endostar combined with CCRT and CCRT for locally advanced NSCLC were included. The primary endpoints were risk ratios (RRs) for objective response rate (ORR) and disease control rate (DCR). The secondary endpoints were RRs for overall survival (OS) and adverse events (AEs). Results Ten studies with 716 patients were included in this meta‐analysis. Endostar combined with CCRT significantly improved ORR and DCR compared with CCRT. The RRs of ORR and DCR for endostar combined with CCRT versus CCRT were 1.263 (95% CI: 1.137–1.403, p < 0.001) and 1.274 (95% CI: 1.124–1.444, p < 0.001), respectively. Endostar combined with CCRT significantly improved one‐year survival rate compared with CCRT with pooled RR = 1.113 (95% CI: 1.006–1.231, p = 0.038). Endostar combination treatments had similar incidences of main adverse events compared with CCRT (p > 0.05). Conclusion Endostar combined with CCRT is associated with significantly higher ORR, DCR and survival rate than CCRT with similar incidences of main adverse events in NSCLC.
format	article
author	Meng Yuan Yirui Zhai Yu Men Jianyang Wang Lei Deng Wenqing Wang Yongxing Bao Xu Yang Shuang Sun Zeliang Ma Yunsong Liu Jun Wang Hui Zhu Zhouguang Hui
author_facet	Meng Yuan Yirui Zhai Yu Men Jianyang Wang Lei Deng Wenqing Wang Yongxing Bao Xu Yang Shuang Sun Zeliang Ma Yunsong Liu Jun Wang Hui Zhu Zhouguang Hui
author_sort	Meng Yuan
title	Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
title_short	Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
title_full	Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
title_fullStr	Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
title_full_unstemmed	Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
title_sort	endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: a systematic review and meta‐analysis
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/a597e61c70d744ec9bc1c2305f16b691
work_keys_str_mv	AT mengyuan endostarrhendostatinimprovesefficacyofconcurrentchemoradiotherapyforlocallyadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT yiruizhai endostarrhendostatinimprovesefficacyofconcurrentchemoradiotherapyforlocallyadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT yumen endostarrhendostatinimprovesefficacyofconcurrentchemoradiotherapyforlocallyadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT jianyangwang endostarrhendostatinimprovesefficacyofconcurrentchemoradiotherapyforlocallyadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT leideng endostarrhendostatinimprovesefficacyofconcurrentchemoradiotherapyforlocallyadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT wenqingwang endostarrhendostatinimprovesefficacyofconcurrentchemoradiotherapyforlocallyadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT yongxingbao endostarrhendostatinimprovesefficacyofconcurrentchemoradiotherapyforlocallyadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT xuyang endostarrhendostatinimprovesefficacyofconcurrentchemoradiotherapyforlocallyadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT shuangsun endostarrhendostatinimprovesefficacyofconcurrentchemoradiotherapyforlocallyadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT zeliangma endostarrhendostatinimprovesefficacyofconcurrentchemoradiotherapyforlocallyadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT yunsongliu endostarrhendostatinimprovesefficacyofconcurrentchemoradiotherapyforlocallyadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT junwang endostarrhendostatinimprovesefficacyofconcurrentchemoradiotherapyforlocallyadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT huizhu endostarrhendostatinimprovesefficacyofconcurrentchemoradiotherapyforlocallyadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT zhouguanghui endostarrhendostatinimprovesefficacyofconcurrentchemoradiotherapyforlocallyadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
_version_	1718402368076251136

Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis

Ejemplares similares